EXHIBIT 10.17
REGISTRATION RIGHTS AGREEMENT
REGISTRATION RIGHTS AGREEMENT (this "AGREEMENT"), dated as of
November 18, 1996, by and among each of the persons named on SCHEDULE 1 annexed
hereto (each, an "INVESTOR" and collectively, the "INVESTORS"), Gruntal & Co.,
Incorporated ("GRUNTAL), and LifeCell Corporation, a Delaware corporation (the
"COMPANY").
W I T N E S S E T H:
WHEREAS, the Investors and the Company have entered into that
certain Securities Purchase Agreement, dated as of the date hereof (the
"PURCHASE AGREEMENT"), whereby the Investors have purchased (a) an aggregate of
124,157 shares of the Series B Preferred Stock, par value $.001 per share (the
"SERIES B PREFERRED STOCK"), of the Company and (b) warrants (the "WARRANTS";
together with the Series B Preferred Stock, the "SECURITIES") to purchase an
aggregate of 2,803,530 shares (the "WARRANT SHARES") of common stock, par value
$.001 per share ("COMMON STOCK"), of the Company.
WHEREAS, the Company has on the date hereof granted to Gruntal, the
Company's placement agent in connection with the transactions evidenced by the
Purchase Agreement, a warrant (the "GRUNTAL WARRANT") to purchase 354,734 shares
(the "GRUNTAL WARRANT SHARES") of Common Stock in connection with such
transactions.
WHEREAS, the Company desires to grant registration rights to (a) the
Investors with respect to the Warrant Shares and the shares of Common Stock into
which the Series B Preferred Stock is convertible and (b) Gruntal with respect
to the Gruntal Warrant Shares.
NOW, THEREFORE, in consideration of the premises and mutual
covenants and conditions contained herein and of other good and valuable
consideration, the receipt and adequacy of which is hereby acknowledged, Company
and the Investors agree as follows:
ARTICLE 1.
DEFINITIONS
All terms not defined herein or below shall have the meanings
ascribed thereto in the Purchase Agreement.
"EXCHANGE ACT" means the Securities Exchange Act of 1934, as
amended, or any similar federal statute, and the rules and regulations of the
Commission thereunder, all as the same shall be in effect at the time.
"HOLDER" means an Investor or Gruntal, in either case, in its
capacity as a holder of Registrable Securities.
"NASD" shall mean the National Association of Securities Dealers,
Inc.
"REGISTRABLE SECURITIES" means (i) the Warrant Shares, (ii) the
shares of Common Stock issued upon the conversion of shares of the Series B
Preferred Stock issued pursuant to the Purchase Agreement, (iii) the Gruntal
Warrant Shares, (iv) any shares of Common Stock issuable to the Investors
pursuant to the right of first refusal set forth in Section 5 of the Purchase
Agreement, and (v) any additional shares of Common Stock acquired by the Holder
by way of a dividend, stock split or other distribution in respect of the Series
B Preferred Stock. As to any particular Registrable Securities, once issued,
such securities shall cease to be Registrable Securities at such time when (x) a
registration statement with respect to the sale of such securities has been
declared effective by the Commission and such securities have been disposed of
pursuant to such effective registration statement, (y) such securities have been
distributed to the public pursuant to the provisions of Rule 144, or (z) such
securities have ceased to be outstanding. For purposes of this Agreement, a
Person shall be deemed to be a Holder of Registrable Securities, and the
Registrable Securities shall be deemed to be in existence, and such Person shall
be entitled to exercise the rights of a Holder of such Registrable Securities
hereunder, whenever such Person has the right to acquire, directly or
indirectly, such Registrable Securities (upon conversion or exercise in
connection with a transfer of securities or otherwise, but disregarding any
restrictions or limitations upon the exercise of such right), whether or not
such acquisition has actually been effected.
"SECURITIES ACT" means the Securities Act of 1933, as amended, or
any similar federal statute, and the rules and regulations of the Commission
thereunder, all as the same shall be in effect at the time.
"SELLING HOLDER" means an Investor or Gruntal, in either case, in
its capacity as a seller of Registrable Securities pursuant to a registration
statement under the Securities Act.
"UNDERWRITER" means a securities dealer who purchases any
Registrable Securities as principal in an underwritten offering and not as part
of such dealer's market-making activities.
ARTICLE 2.
REGISTRATION RIGHTS
SECTION 2.1 SHELF REGISTRATION.
(a) GENERAL. The Company covenants and agrees with the Investors and
Gruntal that the Company will (i) prepare and file with the Commission no later
than the 75th day following the Closing Date a registration statement under the
Securities Act with respect to the public offering of the Registrable Securities
referred to in clauses (i), (ii) and (iii) of the definition of Registrable
Securities contained in Article I hereof (a "SHELF REGISTRATION"), (ii) use its
best efforts (as used herein the term "best efforts" shall have the meaning
commonly accorded such term as used in registration rights agreements similar to
this Agreement) to have any such registration statement declared effective as
soon as practicable and in any event no later than the 180th day following the
Closing Date and (iii) prepare and file such post-effective amendment or
amendments to such registration statement with respect to Registrable Securities
referred to in clauses (iv) and (v) of the definition of Registrable Securities
contained in Article I hereof. The Company hereby agrees to timely file all
reports required under the Exchange Act for so long as the Company is obligated
to maintain the effectiveness of the registration statement. Once the
registration statement described
- 2 -
in this subsection (a) has been declared effective, the Company shall maintain
the registration statement in effect until (x) all Registrable Securities have
been sold pursuant thereto or (y) no securities are outstanding that constitute
Registrable Securities.
(b) EFFECTIVE REGISTRATION. The Shelf Registration shall not be
deemed to have been effected unless it has been declared effective by the
Commission; PROVIDED, that if, after the registration statement has become
effective, the offering of shares of Common Stock pursuant to such Shelf
Registration is or becomes the subject of any stop order, injunction or other
order or requirement of the Commission or any other governmental or
administrative agency, or if any court prevents or otherwise limits the sale of
the shares of Common Stock pursuant to the Shelf Registration at any time within
180 days after the effective date of the registration statement, the Shelf
Registration shall not be deemed to have been effected. If the Shelf
Registration (i) is deemed not to have been effected or (ii) does not remain
effective for a period of at least 180 days beyond the effective date thereof
or, with respect to an underwritten offering of Registrable Securities, until 45
days after the commencement of the distribution by the Holders of the
Registrable Securities included in such registration statement, then the Company
shall continue to be obligated to effect such Shelf Registration pursuant to
this Section 2.1.
(c) OTHER HOLDERS. No securities other than Registrable Securities
shall be included in the Shelf Registration.
(d) SELECTION OF UNDERWRITER. If the Selling Holders so elect at any
time, the offering of such Registrable Securities pursuant to such Shelf
Registration shall be in the form of an underwritten offering and, if necessary,
the Company shall amend the Shelf Registration to reflect such method of
offering. The Selling Holder holding the largest number of Registrable
Securities to be sold in such underwritten offering shall select one nationally
recognized investment banker to act as the lead managing Underwriter in
connection with such offering; and the Selling Holder holding the second largest
number of Registrable Securities to be sold in such underwritten offering may at
its option select one nationally recognized investment banker to act as the
co-managing Underwriter in connection with such offering.
SECTION 2.2 PIGGY-BACK REGISTRATION.
(a) GENERAL. If at any time the Company proposes to file a
registration statement under the Securities Act with respect to an offering by
the Company for its own account or for the account of any of its respective
security holders (other than a registration statement on Form S-4 or S-8, or any
substitute forms thereof that may be adopted by the Commission), a registration
pursuant to Section 2.1 or any demand registration provided for pursuant to that
certain Underwriters Warrant Agreement dated March 6, 1992, pursuant to which
certain registration rights were granted to ▇▇▇▇▇▇ ▇▇▇▇ Financial Corporation),
then the Company shall give prompt written notice of such proposed filing to the
Holders of Registrable Securities as soon as practicable (but in no event less
than twenty (20) days before the anticipated filing date), and such notice shall
offer such Holders the opportunity to register such number of Registrable
Securities as each such Holder may request (which request shall specify the
Registrable Securities intended to be disposed of by such Holder) (a "PIGGY-BACK
REGISTRATION"). The Company shall use its best efforts to cause the managing
Underwriter or Underwriters of a proposed underwritten offering to permit the
Registrable Securities requested to
- 3 -
be included in a Piggy-Back Registration to be included on the same terms and
conditions as any similar securities of the Company or any other security holder
included therein and to permit the sale or other disposition of such Registrable
Securities in accordance with the intended method of distribution thereof. Any
Holder shall have the right to withdraw its request for inclusion of its
Registrable Securities in any registration statement pursuant to this Section
2.2 by giving written notice to the Company of its request to withdraw. The
Company may withdraw a Piggy-Back Registration at any time prior to the time it
becomes effective.
No registration effected under this Section 2.2, and no failure to
effect a registration under this Section 2.2, shall relieve the Company of its
obligation to effect a Shelf Registration pursuant to Section 2.1, and no
failure to effect a registration under this Section 2.2 and to complete the sale
of Registrable Securities in connection therewith shall relieve the Company of
any other obligation under this Agreement (including, without limitation, the
Company's obligations under Sections 3.2 and 4.1).
(b) REDUCTION. Notwithstanding anything to the contrary contained
herein, if the managing Underwriter or Underwriters of any underwritten offering
described in this Section 2.2 have informed, in writing, the Holders of the
Registrable Securities requesting inclusion in such offering that it is their
opinion that the total number of shares which the Company, Holders of
Registrable Securities and any other holders of securities of the Company
desiring to participate in such registration intend to include in such offering
is such as to materially and adversely affect the success of such offering, then
the number of shares to be offered shall be reduced or limited in the following
order of priority: FIRST, the number of shares to be offered by all other
holders of securities of the Company (other than the Holders of Registrable
Securities and other holders of securities of the Company who have registration
rights, as set forth on SCHEDULE 2.2(B) annexed hereto (collectively, the "OTHER
HOLDERS")) to the extent necessary to reduce the total number of shares as
recommended by such managing Underwriters; and SECOND, if further reduction or
limitation is required, the number of shares to be offered for the account of
the Holders and the Other Holders shall be reduced or limited on a PRO RATA
basis in proportion to the relative number of securities of the Holders and
Other Holders participating in such registration. If, as a result of the
proration provisions of this Section 2.2, any Holder shall not be entitled to
include at least 50% of the Registrable Securities in a Piggy-Back Registration
in which such Holder has requested to be included, such Holder may elect to
withdraw his, her or its request to include such Holder's Registrable Securities
in such registration (a "WITHDRAWAL ELECTION"); PROVIDED, HOWEVER, that a
Withdrawal Election shall be irrevocable and, after making a Withdrawal
Election, a Holder shall no longer have any right to include Registrable
Securities in the Piggy-Back Registration as to which such Withdrawal Election
was made.
ARTICLE 3.
REGISTRATION PROCEDURES
SECTION 3.1 FILINGS; INFORMATION. In connection with the Shelf
Registration (including any underwritten public offering pursuant to Section
2.1(d) hereof) or any Piggyback Registration, the Company will use its best
efforts to effect the registration and the sale of such Registrable Securities
in accordance with the intended method of disposition thereof as quickly as
practicable, and in connection with any such request:
- 4 -
(a) REGISTRATION STATEMENTS. The Company will prepare and file with
the Commission a registration statement with respect to such Registrable
Securities (which, in the case of any underwritten public offering, shall
include such additional information in the prospectus included therein as shall
be reasonably requested by the managing Underwriter or Underwriters) and use its
best efforts to cause such registration statement to become and remain effective
until the completion of the distribution or until the Company's obligations
otherwise terminate hereunder.
(b) AMENDMENTS AND SUPPLEMENTS. The Company will prepare and file
with the Commission such amendments and supplements to such registration
statement and the prospectus used in connection therewith as may be necessary to
keep such registration statement effective for the period specified in
subsection (a) above and as to comply with the provisions of the Securities Act
with respect to the disposition of all Registrable Securities covered by such
registration statement in accordance with the intended method of disposition set
forth in such registration statement for such period.
(c) COPIES FOR REVIEW. The Company will, as far in advance as
practical, prior to filing a registration statement or prospectus or any
amendment or supplement thereto, furnish copies of such registration statement
as proposed to be filed, together with exhibits thereto, to (i) each Selling
Holder, (ii) not more than one counsel representing all Selling Holders, to be
selected by a majority-in-interest of such Selling Holders, and (iii) each
Underwriter, if any, of the Registrable Securities covered by such registration
statement, which documents will be subject to review and approval by the
foregoing within five (5) days after delivery, and thereafter as far in advance
as practical, furnish to such Selling Holders, counsel and Underwriters, if any,
for their review and comment such number of copies of such registration
statement, each amendment and supplement thereto (in each case including all
exhibits thereto and documents incorporated by reference therein), the
prospectus included in such registration statement (including each preliminary
prospectus) and such other documents or information as such Selling Holders,
counsel or Underwriters may reasonably request in order to facilitate the
disposition of the Registrable Securities owned by such Selling Holders.
(d) STOP ORDERS. After the filing of the registration statement, the
Company will promptly notify each Selling Holder of Registrable Securities
covered by such registration statement of any stop order issued or threatened by
the Commission and take all reasonable actions required to prevent the entry of
such stop order or to remove it if entered.
(e) BLUE SKY. The Company will use its best efforts to (i) register
or qualify the Registrable Securities under such other securities or blue sky
laws of such jurisdictions in the United States as any Selling Holder reasonably
(in light of such Selling Holder's intended plan of distribution) requests, and
(ii) cause such Registrable Securities to be registered with or approved by such
other governmental agencies or authorities in the United States as may be
necessary by virtue of the business and operations of the Company and do any and
all other acts and things that may be reasonably necessary or advisable to
enable such Selling Holder to consummate the disposition of the Registrable
Securities owned by such Selling Holder; PROVIDED, that the Company will not be
required to (x) qualify generally to do business in any jurisdiction where it
would not otherwise be required to qualify but for this subsection (e), (y)
subject itself to taxation in any such jurisdiction or (z) consent to general
service of process in any such jurisdiction.
- 5 -
(f) CERTAIN EVENTS. The Company will immediately notify each Selling
Holder, at any time when a prospectus relating thereto is required to be
delivered under the Securities Act, of the occurrence of an event requiring the
preparation of a supplement or amendment to such prospectus so that, as
thereafter delivered to the Holders of such Registrable Securities, such
prospectus will not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made,
not misleading and promptly make available to each Selling Holder any such
supplement or amendment. The Company will promptly prepare and if required,
cause to become effective, such supplement or amendment and deliver sufficient
copies thereof to each Selling Holder.
(g) AGREEMENTS. The Company and the Selling Holders will enter into
customary agreements (including, if applicable, an underwriting agreement in
customary form and which is reasonably satisfactory to the Company) and take
such other actions as are reasonably required in order to expedite or facilitate
the disposition of such Registrable Securities; and the Selling Holders may, at
their option, require that any or all of the representations, warranties and
covenants of the Company or to or for the benefit of such Underwriters also be
made to and for the benefit of such Selling Holders.
(h) DUE DILIGENCE. The Company will make available to each Selling
Holder (and their counsel) and each Underwriter, if any, subject to restrictions
imposed by the United States federal government or any agency or instrumentality
thereof, copies of all correspondence between the Commission and the Company,
its counsel or auditors and will also make available for inspection by any
Selling Holder, any Underwriter participating in any disposition pursuant to
such registration statement and any attorney, accountant or other professional
retained by any such Selling Holder or Underwriter (collectively, the
"INSPECTORS"), all financial and other records, pertinent corporate documents
and properties of the Company (collectively, the "RECORDS") as shall be
reasonably necessary to enable them to exercise their due diligence
responsibility, and cause the Company's officers and employees to supply all
information reasonably requested by any Inspectors in connection with such
registration statement. Records which the Company determines, in good faith, to
be confidential and which it notifies the Inspectors are confidential shall not
be disclosed by the Inspectors unless (i) the disclosure of such Records is
necessary to avoid or correct a misstatement or omission in such registration
statement or (ii) the disclosure or release of such Records is requested or
required pursuant to oral questions, interrogatories, requests for information
or documents or a subpoena or other order from a court of competent jurisdiction
or other process; PROVIDED, that prior to any disclosure or release pursuant to
clause (ii), the Inspectors shall provide the Company with prompt notice of any
such request or requirement so that the Company may seek an appropriate
protective order or waive such Inspectors' obligation not to disclose such
Records; and, PROVIDED FURTHER, that if failing the entry of a protective order
or the waiver by the Company permitting the disclosure or release of such
Records, the Inspectors, upon advice of counsel, are compelled to disclose such
Records, the Inspectors may disclose that portion of the Records which counsel
has advised the Inspectors that the Inspectors are compelled to disclose. Each
Selling Holder agrees that information obtained by it solely as a result of such
inspections (not including any information obtained from a third party who,
insofar as is known to the Selling Holder after reasonable inquiry, is not
prohibited from providing such information by a contractual, legal or fiduciary
obligation to the Company) shall be deemed confidential and shall not be used by
it as the
- 6 -
basis for any market transactions in the securities of the Company or its
affiliates (as defined in Rule 405 promulgated under the Securities Act) unless
and until such information is made generally available to the public. Each
Selling Holder further agrees that it will, upon learning that disclosure of
such Records is sought in a court of competent jurisdiction, give notice to the
Company and allow the Company, at its expense, to undertake appropriate action
to prevent disclosure of the Records deemed confidential.
(i) SALES EFFORTS. In connection with an underwritten offering, the
Company will participate, to the extent reasonably requested by the managing
Underwriter for the offering or the Selling Holders, in customary efforts to
sell the securities under the offering, including, without limitation,
participating in "road shows"; PROVIDED, that the Company shall not be obligated
to participate in more than one such offering in any 12-month period.
The Company may require each Selling Holder to promptly furnish in
writing to the Company such information regarding the distribution of the
Registrable Securities as the Company may from time to time reasonably request
and such other information as may be legally required in connection with such
registration including, without limitation, all such information as may be
requested by the Commission or the NASD. The Company may exclude from such
registration any Holder who fails to provide such information.
Each Selling Holder agrees that, upon receipt of any notice from the
Company of the happening of any event of the kind described in subsection (f)
hereof, such Selling Holder will forthwith discontinue disposition of
Registrable Securities pursuant to the registration statement covering such
Registrable Securities until such Selling Holder's receipt of the copies of the
supplemented or amended prospectus contemplated by subsection (f) hereof, and,
if so directed by the Company, such Selling Holder will deliver to the Company
all copies, other than permanent file copies then in such Selling Holder's
possession, of the most recent prospectus covering such Registrable Securities
at the time of receipt of such notice.
SECTION 3.2 REGISTRATION EXPENSES. In connection with the Shelf
Registration and any Piggy-Back Registration, the Company shall pay the
following registration expenses incurred in connection with the registration
thereunder (the "REGISTRATION EXPENSES"): (i) all registration and filing fees,
(ii) fees and expenses of compliance with securities or blue sky laws (including
reasonable fees and disbursements of counsel in connection with blue sky
qualifications of the Registrable Securities), (iii) processing, duplicating and
printing expenses, (iv) the Company's internal expenses (including, without
limitation, all salaries and expenses of its officers and employees performing
legal or accounting duties), (v) the fees and expenses incurred in connection
with the listing of the Registrable Securities, (vi) reasonable fees and
disbursements of counsel for the Company and customary fees and expenses for
independent certified public accountants retained by the Company (including the
expenses of any comfort letters or costs associated with the delivery by
independent certified public accountants of a comfort letter or comfort letters
requested but not the cost of any audit other than a year end audit), (vii) the
reasonable fees and expenses of any special experts retained by the Company in
connection with such registration, (viii) reasonable fees and expenses of one
firm of counsel for the Holders to be selected by the Holders of at least 66.67%
of the Registrable Securities to be included in such registration, and (ix) any
other fees and disbursements of underwriters customarily paid by issuers or
sellers of securities. The Company
- 7 -
shall have no obligation to pay any other underwriting fees, discounts or
commissions attributable to the sale of Registrable Securities, or the cost of
any special audit required, such costs to be borne by the Holder or Holders
making the request.
SECTION 3.3 ADVICE BY COMPANY. The Company will keep each Holder
advised as to the completion of any registration contemplated in this Agreement.
At its expense, the Company will furnish promptly to each Holder such number or
copies of prospectuses (including preliminary prospectuses), and all amendments
and supplements thereto, in conformity with the requirements of the Securities
Act, and such other documents as any such Holder from time to time may
reasonably request.
ARTICLE 4.
INDEMNIFICATION AND CONTRIBUTION
SECTION 4.1 INDEMNIFICATION BY THE COMPANY. The Company shall, to
the full extent permitted by law, indemnify and hold harmless each Selling
Holder, its partners, officers, directors, employees and agents, and each
person, if any, who controls such Selling Holder within the meaning of Section
15 of the Securities Act or Section 20 of the Exchange Act, together with the
partners, officers, directors, employees and agents of such controlling person
(collectively, "HOLDER COVERED PERSONS"), from and against any loss, claim,
damage, liability, reasonable attorneys' fees, cost or expense and costs and
expenses of investigating and defending any such claim, joint or several, and
any action in respect thereof (collectively, the "DAMAGES"), to which any such
Holder Covered Person may become subject under the Securities Act or otherwise,
insofar as such Damages (or actions or proceedings, whether commenced or
threatened, in respect thereof) arise out of, or are based upon, any untrue
statement or alleged untrue statement of a material fact contained in any
registration statement or prospectus relating to the Registrable Securities or
any amendment or supplement thereto, or arises out of, or are based upon, any
omission or alleged omission to state therein a material fact required to be
stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading, or any violation by
the Company of any federal or state securities law or any rule or regulation
thereof, except insofar as the same are based upon information furnished in
writing to the Company by a Selling Holder expressly for use therein, and shall
reimburse each Holder Covered Person for any legal and other expenses reasonably
incurred by that Holder Covered Person in investigating or defending or
preparing to defend against any such Damages or proceedings; PROVIDED, HOWEVER,
that the Company shall not be liable to any Selling Holder to the extent that
any such Damages (or action or proceeding in respect thereof) arise out of or
are based upon any untrue statement or omission made in any preliminary
prospectus if (i) such Selling Holder failed to send or deliver a copy of the
final prospectus with or prior to the delivery of written confirmation of the
sale by such Selling Holder to the person asserting the claim from which such
Damages arise, and (ii) the final prospectus would have corrected such untrue
statement or such omission; PROVIDED FURTHER, that the Company shall not be
liable to any Selling Holder in any such case to the extent that any such
Damages arise out of or are based upon any untrue statement or omission in any
prospectus if (x) such untrue statement or omission is corrected in an amendment
or supplement to such prospectus, and (y) having previously been furnished by or
on behalf of the Company with copies of such prospectus as so amended or
supplemented, such Selling Holder thereafter fails to deliver such prospectus as
so amended or supplemented prior to or concurrently with the sale of a
Registrable Security to the person asserting
- 8 -
the claim from which such Damages arise. The Company also agrees to indemnify
any Underwriters of the Registrable Securities, their officers and directors and
each person who controls any such Underwriters on substantially the same basis
as that of the indemnification of the Selling Holders provided in this Section
4.1.
SECTION 4.2 INDEMNIFICATION BY SELLING HOLDERS. Each Selling Holder
shall, to the full extent permitted by law, severally but not jointly, indemnify
and hold harmless the Company, its officers, directors, employees and agents and
each person, if any, who controls the Company within the meaning of Section 15
of the Securities Act or Section 20 of the Exchange Act, together with the
partners, officers, directors, employees and agents of such controlling person
(collectively, "COMPANY COVERED PERSONS"), to the same extent as the foregoing
indemnity from the Company to such Selling Holder, but only with reference to
information related to such Selling Holder, or its plan of distribution,
furnished in writing by such Selling Holder or on such Selling Holder's behalf
expressly for use in any registration statement or prospectus relating to the
Registrable Securities, or any amendment or supplement thereto, or any
preliminary prospectus and the aggregate amount which may be recovered from any
Selling Holder pursuant to the indemnification provided for in this Section 4.2
in connection with any registration and sale of Registrable Securities shall be
limited to the total proceeds received by such Holder from the sale of such
Registrable Securities. In case any action or proceeding shall be brought
against any Company Covered Person in respect of which indemnity may be sought
against such Selling Holder, such Selling Holder shall have the rights and
duties given to the Company Covered Persons, and the Company Covered Persons
shall have the rights and duties given to such Selling Holder, by Section 4.1.
Each Selling Holder also agrees to indemnify and hold harmless any Underwriters
of the Registrable Securities, their officers and directors and each person who
controls such Underwriters on substantially the same basis as that of the
indemnification of the Company provided in this Section 4.2. The Company shall
be entitled to receive indemnities from Underwriters, selling brokers, dealer
managers and similar securities industry professionals participating in the
distribution, to the same extent as provided above, with respect to information
so furnished in writing by such persons specifically for inclusion in any
prospectus or registration statement.
SECTION 4.3 CONDUCT OF INDEMNIFICATION PROCEEDINGS. Promptly after
receipt by any person in respect of which indemnity may be sought pursuant to
Section 4.1 or 4.2 (an "INDEMNIFIED PARTY") of notice of any claim or the
commencement of any action, the Indemnified Party shall, if a claim in respect
thereof is to be made against the person against whom such indemnity may be
sought (an "INDEMNIFYING PARTY"), notify the Indemnifying Party in writing of
the claim or the commencement of such action; PROVIDED that the failure to
notify the Indemnifying Party shall not relieve it from any liability which it
may have to an Indemnified Party otherwise than under Section 4.1 or 4.2 and
except to the extent of any actual prejudice resulting therefrom. If any such
claim or action shall be brought against an Indemnified Party, and it shall
notify the Indemnifying Party thereof, the Indemnifying Party shall be entitled
to participate therein, and, to the extent that it wishes, jointly with any
other similarly notified Indemnifying Party, to assume the defense thereof with
counsel reasonably satisfactory to the Indemnified Party. After notice from the
Indemnifying Party to the Indemnified Party of its election to assume the
defense of such claim or action, the Indemnifying Party shall not be liable to
the Indemnified Party for any legal or other expenses subsequently incurred by
the Indemnified Party in connection with the defense thereof other than
reasonable costs of investigation; PROVIDED that the Indemnified Party shall
have the right to employ
- 9 -
separate counsel to represent the Indemnified Party and its Controlling Persons
who may be subject to liability arising out of any claim in respect of which
indemnity may be sought by the Indemnified Party against the Indemnifying Party,
but the fees and expenses of such counsel shall be for the account of such
Indemnified Party unless (i) the Indemnifying Party and the Indemnified Party
shall have mutually agreed to the retention of such counsel or (ii) in the
reasonable judgment of the Company and such Indemnified Party, representation of
both parties by the same counsel would be inappropriate due to actual or
potential conflicts of interest between them, it being understood, however, that
the Indemnifying Party shall not, in connection with any one such claim or
action or separate but substantially similar or related claims or actions in the
same jurisdiction arising out of the same general allegations or circumstances,
be liable for the fees and expenses of more than one separate firm of attorneys
(together with appropriate local counsel) at any time for all Indemnified
Parties, or for fees and expenses that are not reasonable. No Indemnifying Party
shall, without the prior written consent of the Indemnified Party, effect any
settlement of any claim or pending or threatened proceeding in respect of which
the Indemnified Party is or could have been a party and indemnity could have
been sought hereunder by such Indemnified Party, unless such settlement includes
an unconditional release of such Indemnified Party from all liability arising
out of such claim or proceeding. Whether or not the defense of any claim or
action is assumed by the Indemnifying Party, such Indemnifying Party will not be
subject to any liability for any settlement made without its consent, which
consent will not be unreasonably withheld.
SECTION 4.4 CONTRIBUTION. If the indemnification provided for in
this Article 4 is unavailable to the Indemnified Parties in respect of any
Damages referred to herein, then each Indemnifying Party, in lieu of
indemnifying such Indemnified Party, shall contribute to the amount paid or
payable by such Indemnified Party as a result of such Damages (i) as between the
Company and the Selling Holders on the one hand and the Underwriters on the
other, in such proportion as is appropriate to reflect the relative benefits
received by the Company and the Selling Holders on the one hand and the
Underwriters on the other from the offering of the Registrable Securities, or if
such allocation is not permitted by applicable law, in such proportion as is
appropriate to reflect not only the relative benefits but also the relative
fault of the Company and the Selling Holders on the one hand and of the
Underwriters on the other in connection with the statements or omissions which
resulted in such Damages, as well as any other relevant equitable
considerations, and (ii) as between the Company on the one hand and each Selling
Holder on the other, in such proportion as is appropriate to reflect the
relative fault of the Company and of each Selling Holder in connection with such
statements or omissions, as well as any other relevant equitable considerations.
The relative benefits received by the Company and the Selling Holders on the one
hand and the Underwriters on the other shall be deemed to be in the same
proportion as the total proceeds from the offering (net of underwriting
discounts and commissions but before deducting expenses) received by the Company
and the Selling Holders bear to the total underwriting discounts and commissions
received by the Underwriters, in each case as set forth in the table on the
cover page of the prospectus. The relative fault of the Company and the Selling
Holders on the one hand and of the Underwriters on the other shall be determined
by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission or alleged omission to state a
material fact relates to information supplied by the Company and the Selling
Holders or by the Underwriters. The relative fault of the Company on the one
hand and of each Selling Holder on the other shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a
material fact or the omission or alleged omission to state a material fact
relates to information
- 10 -
supplied by such party, and the parties' relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission.
The Company and the Selling Holders agree that it would not be just
and equitable if contribution pursuant to this Section 4.4 were determined by
PRO RATA allocation (even if the Underwriters were treated as one entity for
such purpose) or by any other method of allocation which does not take account
of the equitable considerations referred to in the immediately preceding
paragraph. The amount paid or payable by an Indemnified Party as a result of the
Damages referred to in the immediately preceding paragraph shall be deemed to
include, subject to the limitations set forth above, any legal or other expenses
reasonably incurred by such Indemnified Party in connection with investigating
or defending any such action or claim. Notwithstanding the provisions of this
Section 4.4, no Underwriter shall be required to contribute any amount in excess
of the amount by which the total price at which the Registrable Securities
underwritten by it and distributed to the public were offered to the public
exceeds the amount of any damages which such Underwriter has otherwise been
required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission, and no Selling Holder shall be required to contribute any
amount in excess of the amount by which the total price at which the Registrable
Securities of such Selling Holder were offered to the public (less underwriting
discounts and commissions) exceeds the amount of any damages which such Selling
Holder has otherwise been required to pay by reason of such untrue or alleged
untrue statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. Each Selling Holder's obligations to contribute
pursuant to this Section 4.4 is several in the proportion that the proceeds of
the offering received by such Selling Holder bears to the total proceeds of the
offering received by all the Selling Holders and not joint.
ARTICLE 5.
MISCELLANEOUS
SECTION 5.1 OTHER REGISTRATION RIGHTS; HOLDBACK. The Company
represents and warrants to the Holders that, except as set forth on SCHEDULE
2.2(B), there is not in effect on the date hereof any agreement by the Company
pursuant to which any holders of securities of the Company have a right to cause
the Company to register or qualify such securities under the Securities Act or
any securities or blue sky laws of any jurisdiction that would conflict in any
material respect with any provision of this Agreement. The Company shall not in
the future grant to any owner or purchaser of shares of capital stock of the
Company registration rights unless (a) such registration rights are made
subordinate to the rights granted hereunder so that each Holder shall have
priority to participate in any piggy-back registration with respect to such
other shares of capital stock of the Company and (b) if the offering by the
Holders is underwritten, such owner or purchaser agrees not to sell any shares
of capital stock of the Company during the period commencing ten (10) days prior
to any such underwritten offering and ending ninety (90) days following any such
underwritten offering (or for such shorter period of time as is sufficient and
appropriate, in the opinion of any managing Underwriter(s)). If requested by
managing Underwriter(s) in any such registration, the Company shall request the
directors and executive officers of the Company to execute and deliver similar
holdback agreements.
- 11 -
SECTION 5.2 PARTICIPATION IN UNDERWRITTEN REGISTRATIONS. No person
may participate in any underwritten registration hereunder unless such person
(a) agrees to sell such person's securities on the basis provided in any
underwriting arrangements approved by the persons entitled hereunder to approve
such arrangements, and (b) completes and executes all questionnaires, powers of
attorney, indemnities, underwriting agreements and other documents reasonably
required under the terms of such underwriting arrangements and these
registration rights. Notwithstanding the foregoing, no Holder of Registrable
Securities shall be required to make any representations or warranties to or
agreements with the Company or the Underwriters other than those customarily
made by selling stockholders in such registrations, including without limitation
representations, warranties or agreements regarding such Holder and its
ownership of the securities being registered on its behalf and such Holder's
intended method of distribution and any other representation required by law.
SECTION 5.3 HOLDBACK AGREEMENT. For so long as the Holder has the
right to have Registrable Securities included in any registration pursuant to
this Agreement, the Holder agrees in connection with any underwritten
registration of the Company's securities, upon the request of the Underwriters
managing such underwritten offering of the Company's securities, not to effect
any public sale or distribution (including any sale pursuant to Rule 144 under
the Securities Act) of any Registrable Securities without the prior written
consent of the Company or such Underwriters, as the case may be, within ten (10)
days prior to or ninety (90) days after the effective date of such registration,
as the Company or the Underwriters may specify.
SECTION 5.4 SUSPENSION OF TRADING. After the Company has filed any
registration statement pursuant to this Agreement, and if such registration
shall be in connection with an underwritten offering of the Company's
securities, upon the request of the managing Underwriter or Underwriters the
Company may suspend the sale of Common Stock for up to ninety (90) days;
PROVIDED, HOWEVER, that no such suspension shall occur on more than one occasion
within any one year period.
SECTION 5.5 RULE 144 AND 144A. The Company covenants that it will
file any reports required to be filed by it under the Securities Act and the
Exchange Act and that it will take such further action as any Holder may
reasonably request, all to the extent required from time to time to enable
Holders to sell Registrable Securities without registration under the Securities
Act within the limitation of the exemptions provided by (a) Rule 144 or Rule
144A under the Securities Act, as such Rules may be amended from time to time,
or (b) any similar rule or regulation hereafter adopted by the Commission. Upon
the request of any Holder, the Company will deliver to such Holder a written
statement as to whether it has complied with such requirements.
SECTION 5.6 SUSPENSION OF OBLIGATION TO FILE. Notwithstanding the
provisions of Section 3.1(a), the Company's obligations to file a registration
statement, or cause such registration statement to become and remain effective,
shall be suspended for a period not to exceed 90 days if there exists at the
time material non-public information relating to the Company that, in the
reasonable opinion of the Company, should not be disclosed.
SECTION 5.7 GENERAL.
- 12 -
(a) GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED
IN ACCORDANCE WITH THE INTERNAL LAW OF THE STATE OF NEW YORK, WITHOUT GIVING
EFFECT TO PRINCIPLES OF CONFLICTS OF LAW.
(b) NOTICES. All notices or other communications shall be in writing
and shall be personally served or mailed, registered or certified, return
receipt requested, postage prepaid (or by a substantially similar method), or
delivered by a reputable overnight courier service with charges prepaid, or
transmitted by hand delivery or facsimile, addressed as set forth below, or such
other address as such party shall have specified most recently by written
notice:
If to the Company:
LifeCell Corporation
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇
Attention: President
Telephone: (▇▇▇) ▇▇▇-▇▇▇▇
Telecopy: (▇▇▇) ▇▇▇-▇▇▇▇
with a copy to:
Fulbright & ▇▇▇▇▇▇▇▇ L.L.P.
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇
Attention: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, Esq.
Telephone: (▇▇▇) ▇▇▇-▇▇▇▇
Telecopy: (▇▇▇) ▇▇▇-▇▇▇▇
Notice to any Holder shall be sent to the address listed on SCHEDULE
1 or to such other address which the Holder shall have provided in writing in
accordance with this Section 5.7(b).
Notice shall be deemed given or delivered on the date of service or
transmission if personally served or transmitted by telecopier (with telephonic
confirmation of receipt). Notice otherwise sent as provided herein shall be
deemed given or delivered on the third business day following the date of
postmark or on the next business day following delivery of such notice to a
reputable overnight courier service.
(c) BINDING EFFECT. This Agreement and all of the provisions hereof
shall be binding upon and inure to the benefit of the parties hereto and their
respective heirs, successors and permitted assigns.
(d) NO WAIVER. No failure on the part of the Company or the
Investors in exercising any right, power or privilege granted hereunder shall
operate as a waiver thereof or of any other right, power or privilege, nor shall
any single or partial exercise of such right, power or privilege preclude any
other or further exercise thereof or of any other right, power or privilege.
- 13 -
(e) ENTIRE AGREEMENT. This Agreement sets forth the entire agreement
among the parties hereto with respect to the subject matter hereof, and
supersedes any prior oral or written agreements among the parties.
(f) HEADINGS. The headings of this Agreement are solely for the
convenience of the parties and shall not affect the interpretation or effect of
any terms or provisions hereof.
(g) COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original, but all of which
together shall constitute one and the same document.
(h) SEVERABILITY. In the event that any court or any governmental
authority or agency declares all or any part of any Section of this Agreement to
be unlawful or invalid, such unlawfulness or invalidity shall not serve to
invalidate any other Section of this Agreement, and in the event that only a
portion of any Section is so declared to be unlawful or invalid, such
unlawfulness or invalidity shall not serve to invalidate the balance of such
Section.
(i) AMENDMENTS AND WAIVERS. This Agreement may be amended, modified
and supplemented, and compliance with any term, covenant, agreement or condition
contained herein may be waived either generally or in particular instances, only
by a written instrument executed by the Company and the holders of at least a
majority of the then outstanding Registrable Securities (for this purpose,
treating (i) the Series B Preferred Stock as if it had been converted into
Common Stock and (ii) each of the Warrants and the Gruntal Warrant that is then
exercisable pursuant to its terms as if it had been exercised in full). No
course of dealing between or among any persons having any interest in this
Agreement will be deemed effective to modify, amend or discharge any part of
this Agreement or any rights or obligations of any person under or by reason of
this Agreement.
(j) FURTHER ASSURANCES. Each party shall cooperate and take such
action as may be reasonably requested by another party in order to carry out the
provisions and purposes of this Agreement and the transactions contemplated
hereby.
(k) REMEDIES. In the event of a breach or a threatened breach by any
party to this Agreement of its obligations under this Agreement, any party
injured or to be injured by such breach will be entitled to specific performance
of its rights under this Agreement or to injunctive relief, in addition to being
entitled to exercise all rights provided in this Agreement and granted by law.
The parties agree that the provisions of this Agreement shall be specifically
enforceable, it being agreed by the parties that the remedy at law, inducing
monetary damages, for breach of any such provision will be inadequate
compensation for any loss and that any defense or objection in any action for
specific performance or injunctive relief that a remedy at law would be adequate
is waived.
* * * * *
- 14 -
IN WITNESS WHEREOF, the parties hereto have executed this Agreement
as of the date first above written.
LIFECELL CORPORATION
By /s/▇▇▇▇ ▇. ▇▇▇▇▇▇
▇▇▇▇ ▇. ▇▇▇▇▇▇
President and Chief Executive Officer
VECTOR LATER-STAGE EQUITY FUND, L.P.
By Vector Fund Management, L.P., its General Partner
By Unreadable Signature
Its President
CIBC WOOD GUNDY VENTURES, INC.
By /s/▇▇▇▇ ▇▇▇▇▇▇▇
Name:▇▇▇▇ ▇▇▇▇▇▇▇
Title:Managing Director
- 15 -
GRUNTAL & CO., INCORPORATED
By
Name:
Title:
- 16 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇ ▇▇▇▇
(Signature)
Name: ▇▇▇▇▇ ▇▇▇▇
- 17 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
The Woodlands Venture Capital Company
By: /S/ ▇▇▇ ▇. ▇▇▇▇▇, ▇▇.
(Signature)
Name: ▇▇▇ ▇. ▇▇▇▇▇, ▇▇.
Vice President and Controller
- 18 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ ▇▇▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇.
(Signature)
Name: ▇▇▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇.
- 19 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ P. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, M.D.
(Signature)
Name: P. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
- 20 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 6th day of November, 1996.
/S/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
- 21 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
Managing Director of the General
Partner, S.B.S.F. Biotechnology
Partners, L.P.
- 22 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
- 23 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇ ▇. ▇▇▇
(Signature)
Name: ▇▇▇▇ ▇. ▇▇▇
- 24 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
- 25 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇ ▇. ▇▇▇▇ /S/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇ ▇. ▇▇▇▇
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
- 26 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇ ▇. ▇▇▇▇, TRUSTEE
(Signature)
Name: ▇▇▇▇▇ ▇. ▇▇▇▇, Trustee F/B/O
▇▇▇▇▇▇ ▇. ▇▇▇▇
- 27 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/S/ ▇▇▇▇ ▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇ ▇▇▇▇▇▇▇
- 28 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ B. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
(Signature)
Name: B. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
- 29 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/S/ ▇▇▇▇ ▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇ ▇▇▇▇▇▇▇
- 30 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇ ▇▇▇▇▇▇▇▇▇
- 31 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
- 32 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
/S/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇ & ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
- 33 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇,
General Partner
Chinook Equities
- 34 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/S/ ▇▇▇▇▇ ▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇
- 35 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
- 36 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
- 37 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇▇ ▇. Strazullo
- 38 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
- 39 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/S/ ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
- 40 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
- 41 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 31st day of October, 1996.
/S/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
- 42 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
/S/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
- 43 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
- 44 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
/S/ ▇▇▇▇▇ ▇▇▇▇▇▇ /S/ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
- 45 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇ ▇. ▇▇▇▇▇
/S/ ▇▇▇▇ ▇. ▇▇▇▇▇
(Signature)
Name: ▇▇▇▇ ▇. ▇▇▇▇▇ & ▇▇▇▇ ▇. ▇▇▇▇▇
- 46 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
- 47 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, as Trustee
- 48 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
- 49 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 5th day of November, 1996.
/S/ ▇▇▇▇▇ ▇. ▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇
- 50 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ ▇▇▇▇▇ ▇. ▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇
- 51 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
- 52 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this ____ day of November, 1996.
TECHNOLOGY FUNDING MEDICAL
PARTNERS L.L.P.
By: Technology Funding, Inc.
Managing General Partner
By:/S/ ▇▇▇▇▇▇ ▇. TOY
Name: ▇▇▇▇▇▇ ▇. Toy
Vice President
- 53 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 2nd day of November, 1996.
/S/ ▇▇▇▇▇▇ ▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇
- 54 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
- 55 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ ▇. ▇. ▇▇▇▇▇
(Signature)
Name: ▇. ▇. ▇▇▇▇▇
- 56 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇ & Co. Custodian
- 57 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
- 58 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 2nd day of November, 1996.
/S/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇
- 59 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 11th day of November, 1996.
/S/ ▇▇▇ ▇. ▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇ ▇. ▇▇▇▇▇▇▇
- 60 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
- 61 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ AS GENERAL PARTNER
(Signature)
Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ as General Partner
- 62 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 4th day of November, 1996.
/S/ ▇▇▇▇ ▇▇▇▇
(Signature)
Name: ▇▇▇▇ ▇▇▇▇
Namax Corp. - President
- 63 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 1st day of November, 1996.
/S/ ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
Managing Director of the General
Partner, S.B.S.F. Biotechnology
Fund, L.P.
- 64 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 6th day of November, 1996.
/S/ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
- 65 -
[REGISTRATION RIGHTS AGREEMENT]
SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT BETWEEN LIFECELL
CORPORATION (THE "COMPANY") AND CERTAIN INVESTORS, RELATING TO THE SALE OF
THE COMPANY'S SERIES B PREFERRED STOCK AND WARRANTS AS DESCRIBED IN THE
COMPANY'S PRIVATE PLACEMENT MEMORANDUM, DATED OCTOBER 29, 1996.
The undersigned hereby authorizes Gruntal & Co., Incorporated to deliver
this signature page to the Company at the closing of the offering of the
Company's offering of Series B Preferred Stock.
Dated this 6th day of November, 1996.
/S/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
(Signature)
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
- 66 -
SCHEDULE 1
INVESTORS
Vector Later-Stage Equity Fund, L.P.
▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
CIBC Wood Gundy Ventures, Inc.
▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
The Woodlands Venture Capital Company
▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
SBSF Biotechnology Fund, L.P.
c/o ▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇
▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ -- ▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
SBSF Biotechnology Partners, L.P.
c/o ▇▇▇▇ ▇▇▇▇▇▇▇▇▇
Spears ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇
▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ -- ▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇ ▇. ▇▇▇▇▇ and ▇▇▇▇ ▇. ▇▇▇▇▇,
as joint tenants
▇▇▇▇ ▇. ▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇ and ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇. ▇▇
▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ and ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇. ▇▇▇▇▇
▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇.
▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇ (▇▇▇▇ ▇▇▇▇▇)
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Chinook Equities, Inc.
▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
- ▇▇ -
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ and ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇. ▇▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇ & Co. Custodian
▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇▇▇ #▇▇
▇▇▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
B. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇▇▇
▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇. ▇▇▇▇, Trustee F/B/O ▇▇▇▇▇▇ ▇. ▇▇▇▇
▇▇▇ ▇. ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇. ▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇. ▇▇▇▇ and ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
▇▇▇ ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇. ▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇ ▇. ▇▇▇
▇▇ ▇▇▇▇ ▇▇▇▇, ▇▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
- 68 -
▇▇▇▇▇ ▇. ▇▇▇▇
▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
P. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, M.D.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇, ▇. #▇▇▇
▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇.
▇▇▇▇▇ ▇▇▇▇▇▇ Inc. ▇▇▇ P/S Custodian
▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
▇▇ ▇. ▇▇▇▇▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇. ▇▇▇▇
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Technology Funding Medical Partners I, L.P.
▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇ ▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇. ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇. ▇▇▇▇▇
▇.▇. ▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇. ▇▇▇▇▇
▇ ▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇▇,
Gruntal & Co., Inc., Custodian
▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇ ▇. ▇▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇. ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Harbour Court L.P., II
▇▇▇ ▇. ▇▇▇▇ ▇▇., ▇▇▇. ▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
Namax Corp.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇ ▇▇▇▇, President
▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇
▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇. ▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇. ▇▇▇▇▇
▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
The ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ Trust
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, Trustee
▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
The ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ Trust,
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, Trustee
▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
- 69 -
Pharmaceutical & Medical Technology Fund
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Strategic Healthcare Fund
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
SCHEDULE 2.2(B)
OTHER REGISTRATION RIGHTS
The holders of capital stock listed below pursuant to the Amended and Restated
Registration Rights Agreement, dated February 26, 1992, as amended, by and among
the Company and the holders of capital stock of the Company identified therein:
Allstate Insurance Company
The Woodlands Venture Fund, L.P.
Tenneco Insurance Ventures, Inc.
The Woodlands Venture Capital Company
Board of Regents of the University of Texas System
Technology Funding Partners III, L.P.
▇▇▇▇ ▇. ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ Financial Corporation pursuant to the Underwriter's Warrant
Agreement, dated March 6, 1992, between the Company and ▇▇▇▇▇▇ ▇▇▇▇ Financial
Corporation, as amended by First Amendment to Underwriter's Warrant Agreement,
dated January 23, 1993, by and between the Company and ▇▇▇▇▇▇ ▇▇▇▇ Financial
Corporation.
Medtronic, Inc. pursuant to the Investment Agreement, dated March 3, 1994, as
amended, between the Company and Medtronic, Inc.
- 70 -
